

**(12) STANDARD PATENT**  
**(19) AUSTRALIAN PATENT OFFICE**

(11) Application No. **AU 2012341416 B2**

(54) Title  
**Method of cryopreservation of tissue derived from pluripotent stem cells**

(51) International Patent Classification(s)  
**C12N 5/074** (2010.01) **C12N 5/0775** (2010.01)  
**C12N 1/04** (2006.01) **C12N 5/0789** (2010.01)  
**C12N 5/0735** (2010.01) **C12N 5/0797** (2010.01)

(21) Application No: **2012341416** (22) Date of Filing: **2012.11.22**

(87) WIPO No: **WO13/077424**

(30) Priority Data

(31)	Number	(32)	Date	(33)	Country
	<b>2011-258208</b>		<b>2011.11.25</b>		<b>JP</b>

(43) Publication Date: **2013.05.30**

(44) Accepted Journal Date: **2018.07.05**

(71) Applicant(s)  
**RIKEN;Sumitomo Chemical Company, Limited**

(72) Inventor(s)  
**Ando, Satoshi;Nakano, Tokushige;Sasai, Yoshiki;Eiraku, Mototsugu**

(74) Agent / Attorney  
**Griffith Hack, GPO Box 4164, Sydney, NSW, 2001, AU**

(56) Related Art  
**JP 2011036196 A**  
**Homayoon Babaei ET AL, "Vitrification of mouse ovaries using ethylene glycol and DMSO as cryoprotectants: histopathological evaluation", Veterinarski Arhiv, 2007, 77: 19-27**  
**WO 2009155430 A2**  
**KASAI M ET AL., "Cryopreservation of animal and human embryos by vitrification", REPROD BIOMED, (200408), vol. 9, no. 2, pages 164 - 70**  
**MUKAIDA T ET AL, "Blastocyst cryopreservation: ultrarapid vitrification using cryoloop technique", REPRODUCTIVE BIOMEDICINE ONLINE, REPRODUCTIVE HEALTHCARE LTD, GB, vol. 6, no. 2, ISSN 1472-6483, (20030101), pages 221 - 225, (20030101)**

(12) 特許協力条約に基づいて公開された国際出願

(19) 世界知的所有権機関  
国際事務局

(43) 国際公開日  
2013 年 5 月 30 日(30.05.2013)



(10) 国際公開番号

WO 2013/077424 A1

- (51) 国際特許分類:  
C12N 5/074 (2010.01) C12N 5/0775 (2010.01)  
C12N 1/04 (2006.01) C12N 5/0789 (2010.01)  
C12N 5/0735 (2010.01) C12N 5/0797 (2010.01)
- (21) 国際出願番号: PCT/JP2012/080365
- (22) 国際出願日: 2012 年 11 月 22 日(22.11.2012)
- (25) 国際出願の言語: 日本語
- (26) 国際公開の言語: 日本語
- (30) 優先権データ:  
特願 2011-258208 2011 年 11 月 25 日(25.11.2011) JP
- (71) 出願人: 住友化学株式会社(SUMITOMO CHEMICAL COMPANY, LIMITED) [JP/JP]; 〒1048260 東京都中央区新川二丁目 2 番 1 号 Tokyo (JP). 独立行政法人理化学研究所(RIKEN) [JP/JP]; 〒3510198 埼玉県和光市広沢 2 番 1 号 Saitama (JP).
- (72) 発明者: 安藤 覚(ANDO, Satoshi); 〒5548558 大阪府大阪市此花区春日出中三丁目 1 番 9 8 号 住友化学株式会社内 Osaka (JP). 中野 徳重(NAKANO, Tokushige); 〒5548558 大阪府大阪市此花区春日出中三丁目 1 番 9 8 号 住友化学株式会社内 Osaka (JP). 笹井 芳樹(SASAI, Yoshiki); 〒6500047 兵庫県神戸市中央区港島南町 2-2-3 独立行政法人理化学研究所 神戸研究所内 Hyogo (JP). 永樂 元次(EIRAKU, Mototsugu); 〒6500047 兵庫県神戸市中央区港島南町 2-2-3 独立行政法人理化学研究所 神戸研究所内 Hyogo (JP).
- (74) 代理人: 高島 一(TAKASHIMA, Hajime); 〒5410044 大阪府大阪市中央区伏見町四丁目 1 番 1 号 明治安田生命大阪御堂筋ビル Osaka (JP).
- (81) 指定国 (表示のない限り、全ての種類の国内保護が可能): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) 指定国 (表示のない限り、全ての種類の広域保護が可能): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), ユーラシア (AM, AZ, BY, KG, KZ, RU, TJ, TM), ヨーロッパ (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- 添付公開書類:  
— 国際調査報告 (条約第 21 条(3))

(54) Title: METHOD OF CRYOPRESERVATION OF TISSUE DERIVED FROM PLURIPOTENT STEM CELLS

(54) 発明の名称: 多能性幹細胞由来の組織の凍結保存方法

(57) Abstract: This invention provides a method of cryopreservation of pluripotent stem cell-derived tissue characterized by involving (1) to (3) below. (1) A first step for bringing the pluripotent stem cell-derived tissue into contact with a cell protection solution containing sulfoxides and chain polyols. (2) A second step for holding, in a cryopreservation solution, the pluripotent stem cell-derived tissue brought into contact with the cell protection solution in the first step. (3) A third step for cryopreservation, in the presence of a coolant, of the pluripotent stem cell-derived tissue held in the cryopreservation solution in the second step. By means of this method, a method can be provided to stably store pluripotent stem cell-derived tissue.

(57) 要約: 本発明は、下記(1)～(3)を含むことを特徴とする多能性幹細胞由来の組織の凍結保存方法を提供する。(1)多能性幹細胞由来の組織にスルホキシドと鎖状ポリオールを含む細胞保護溶液を接触させる第一工程(2)第一工程で細胞保護溶液と接触させた多能性幹細胞由来の組織を凍結保存液に保持する第二工程(3)第二工程で凍結保存液に保持された多能性幹細胞由来の組織を、冷却剤存在下にて凍結保存する第三工程本発明の方法により、多能性幹細胞由来の組織を安定に保存する方法を提供することが可能となる。



WO 2013/077424 A1

## DESCRIPTION

Title of the Invention: METHOD OF CRYOPRESERVATION OF TISSUE  
DERIVED FROM PLURIPOTENT STEM CELL

Technical Field

5 [0001]

The present invention relates to a cryopreservation method of a tissue derived from a pluripotent stem cell.

Background Art

[0002]

10 Tissue is a structure of a cell population that has a conformation in which plural types of cells different in the shape and property are sterically configured in a given pattern.

For example, retinal tissue which is one of the constituent elements of eyeball is a membrane-like tissue  
15 covering the inner wall at the back of the eyeball, and the retinal tissue has a layer structure wherein nerve cells are aligned regularly. Retina contains five kinds of largely-divided nerve cells of visual cell, bipolar cell, horizontal cell, amacrin cell, and ganglion cell. Light is converted to  
20 electric signals by visual cells and the information is transmitted to bipolar cells and horizontal cells via chemical synapses. Bipolar cells form a synaptic connection with amacrin cells and ganglion cells, and the axon of ganglion cell as an optic nerve communicates with the visual center in the  
25 cerebrum. For the treatment of retinal disorders, studies of etiology, studies of efficacy and safety in drug discovery, cell transplantation treatment and the like have heretofore been performed. However, a retinal tissue having a layer structure reflecting the human biological tissue, which becomes  
30 the material for such studies, is difficult to obtain.

In recent years, production of a retinal tissue comparable to the retinal tissue in a living body by inducing differentiation of pluripotent stem cells such as ES cells has been reported (non-patent document 1). To utilize a tissue  
35 obtained by differentiation of pluripotent stem cells for

regenerative medicine, safety test and the like, a stable supply of a large amount of the tissue with a uniform quality is essential. On the other hand, production of various tissues by differentiation of pluripotent stem cells requires a given or longer period of differentiation induction, as shown by, for example, a period of not less than 3 weeks for the production of retinal tissue from human ES cells. Also, efficiency of differentiation induction often changes depending on the treatment for the differentiation induction. Therefore, actual practicalization is difficult when such tissue is prepared one by one when in use, and a technique for preserving said tissue at a stage in the process of differentiation induction has been earnestly desired.

[Document List]

[non-patent document]

[0003]

non-patent document 1: M. Eiraku et al., Nature 472, p51-56 (2011): Self-organizing optic-cup morphogenesis in three-dimensional culture

#### SUMMARY OF THE INVENTION

[0004]

For a stable supply of a large amount of a tissue derived from pluripotent stem cells for use for regenerative medicine, evaluation of safety and efficacy, and the like, the development of a preservation method of the tissue is urgently needed.

[0005]

The present inventors have conducted intensive studies in view of such situation and found a method of stably preserving a tissue derived from a pluripotent stem cell, which resulted in the present invention.

Accordingly, the present invention provides the following.

[1] A method for cryopreserving a tissue derived from a

pluripotent stem cell, comprising the following (1) to (3):

(1) a first step of bringing a tissue derived from a pluripotent stem cell into contact with a cell protection solution that contains sulfoxide and chain polyol,

5 (2) a second step of maintaining, in a cryopreservation solution, the pluripotent stem cell-derived tissue that was brought into contact with the cell protection solution in the first step,

(3) a third step of cryopreserving, in the presence of a coolant, the pluripotent stem cell-derived tissue that was maintained in the cryopreservation solution in the second step,.

[2] The cryopreservation method of the aforementioned [1], wherein the cell protection solution that contains sulfoxide and chain polyol is a cell protection solution that contains  
15 sulfoxide, chain polyol and oligosaccharide.

[3] The cryopreservation method of the aforementioned [2], wherein the cell protection solution has a sulfoxide concentration of 5 to 15%, a chain polyol concentration of 4 to 15%, and an oligosaccharide concentration of 5 to 20%.

20 [4] The cryopreservation method of the aforementioned [2] or [3], wherein the sulfoxide is dimethyl sulfoxide and the chain polyol is ethylene glycol and the oligosaccharide is sucrose.

[5] The cryopreservation method of any of the aforementioned [1] to [4], wherein the aforementioned pluripotent stem cell is  
25 a human pluripotent stem cell.

[6] The cryopreservation method of any of the aforementioned [1] to [5], wherein the tissue is a cranial nerve tissue.

[7] The cryopreservation method of any of the aforementioned [1] to [5], wherein the tissue is a retinal tissue.

30 [8] The cryopreservation method of any of the aforementioned [1] to [7], wherein the third step is performed at a temperature lowering rate of not less than 10°C/min.

[9] The cryopreservation method of any of the aforementioned [1] to [8], wherein the coolant is liquid nitrogen.

35 [10] The cryopreservation method of any of the aforementioned

[1] to [9], wherein the cryopreservation solution is a cryopreservation solution that contains dimethyl sulfoxide, acetamide and propylene glycol.

[11] The cryopreservation method of the aforementioned [10], wherein the concentration of dimethyl sulfoxide is 1 to 4M and the concentration of acetamide is 0.5 to 2M and the concentration of propylene glycol is 1.5 to 6M.

[12] A cell protection solution for cryopreservation of a tissue derived from a pluripotent stem cell, which comprises sulfoxide and chain polyol.

[13] The cell protection solution of the aforementioned [12], which further comprises oligosaccharide.

The present invention as claimed herein is described in the following items 1 to 12:

1. A method for cryopreserving a tissue derived from a pluripotent stem cell, comprising the following (1) to (3):
  - (1) a first step of bringing a tissue derived from a pluripotent stem cell into contact at 0°C to 8°C with a first solution that is a cell protection solution and contains sulfoxide and chain polyol,
  - (2) a second step of maintaining, in a second solution that is a cryopreservation solution, the pluripotent stem cell-derived tissue that was brought into contact with the cell protection solution in the first step, and
  - (3) a third step of cryopreserving, in the presence of a coolant, the pluripotent stem cell-derived tissue that was maintained in the cryopreservation solution in the second step;wherein the sulfoxide is dimethyl sulfoxide and the chain polyol is ethylene glycol.
2. The cryopreservation method according to item 1, wherein the cell protection solution that contains sulfoxide and chain polyol is a cell protection solution that contains sulfoxide, chain polyol and oligosaccharide.
3. The cryopreservation method according to item 2, wherein the cell protection solution has a sulfoxide concentration of 5 to 15%, a chain polyol concentration of 4 to 15%, and

an oligosaccharide concentration of 5 to 20%.

4. The cryopreservation method according to item 2 or 3, wherein the oligosaccharide is sucrose.

5. The cryopreservation method according to any one of items 1 to 4, wherein said pluripotent stem cell is a human pluripotent stem cell.

6. The cryopreservation method according to any one of items 1 to 5, wherein the tissue is a cranial nerve tissue.

7. The cryopreservation method according to any one of items 1 to 5, wherein the tissue is a retinal tissue.

8. The cryopreservation method according to any one of items 1 to 7, wherein the third step is performed at a temperature lowering rate of not less than 10°C/min.

9. The cryopreservation method according to any one of items 1 to 7, wherein the third step is performed at a temperature lowering rate of 0.1 to 10°C/min.

10. The cryopreservation method according to any one of items 1 to 9, wherein the coolant is liquid nitrogen.

11. The cryopreservation method according to any one of items 1 to 10, wherein the cryopreservation solution is a cryopreservation solution that contains dimethyl sulfoxide, acetamide and propylene glycol.

12. The cryopreservation method according to item 11, wherein the concentration of dimethyl sulfoxide is 1 to 4M and the concentration of acetamide is 0.5 to 2M and the concentration of propylene glycol is 1.5 to 6M.

#### Effect of the Invention

[0006]

The present invention enables stable preservation of a tissue derived from a pluripotent stem cell.

#### Brief Description of the Drawings

[0007]

Fig. 1 is a view that shows a light field image of retinal tissues generated in the aggregates obtained by differentiation

induction of RAX:: green fluorescent protein (hereinafter, sometimes referred to as "GFP") knock-in human ES cells.

Fig. 2 is a view that shows a fluorescence image of aggregates having the retinal tissue shown in Fig. 1.

Fig. 3 is a view that shows a light field image of retinal tissues cultured after separation from the aggregates.

Fig. 4 is a view that shows a fluorescence image of the retinal tissues shown in Fig. 3.

Fig. 5 is a view that shows the results of immunostaining of frozen sections of retinal tissues cultured after separation from the aggregates with anti-GFP antibody, anti-Chx10 antibody, anti-Pax6 antibody, or anti-Brn3 antibody.

Fig. 6 is a view that shows the state of retinal tissues cultured after separation from the aggregates, which were not



frozen as a control of the experiment (A, B), frozen without contact with a cell protection solution (C, D), frozen after a penetration treatment with a solution containing 11.0% (w/v) dimethyl sulfoxide (DMSO) (E, F), frozen after a penetration  
5 treatment with a solution containing 11.0% (w/v) dimethyl sulfoxide (DMSO) and 5.55% (w/v) ethylene glycol (G, H), and frozen after a penetration treatment with a solution containing 11.0% (w/v) dimethyl sulfoxide (DMSO), 5.55% (w/v) ethylene glycol and 10% (w/v) sucrose (I, J).

10 Fig. 7 is a view that shows the state of retinal tissues cultured after separation from the aggregates, which were not frozen as a control of the experiment (A, B), frozen after a penetration treatment with a solution containing 5% (w/v) sucrose (C, D), frozen after a penetration treatment with a  
15 solution containing 10% (w/v) sucrose (E, F), frozen after a penetration treatment with a solution containing 20% (w/v) sucrose (G, H), frozen after a penetration treatment with a solution containing 11.0% (w/v) dimethyl sulfoxide (DMSO) and 10% (w/v) sucrose (I, J), frozen after a penetration treatment  
20 with a solution containing 5.55% (w/v) ethylene glycol and 10% (w/v) sucrose (K, L).

Fig. 8 is a view that shows the results of immunostaining with anti-GFP antibody (A, C, E), anti-Chx10 antibody (B), anti-Chx10 and anti-Pax6 antibody (D), anti-Chx10 and anti-TuJ1  
25 antibody (F) of frozen sections of the retinal tissues cultured after separation from the aggregates, which were frozen after a penetration treatment with a solution containing 11.0% (w/v) dimethyl sulfoxide (DMSO) and 5.55% (w/v) ethylene glycol (A, B) and a penetration treatment with a solution containing 11.0%  
30 (w/v) dimethyl sulfoxide (DMSO), 5.55% (w/v) ethylene glycol and 10% (w/v) sucrose (C, D, E, F).

Mode(s) for Carrying out the Invention

[0008]

The mode(s) for carrying out the present invention  
35 is(are) explained in detail below.

In the present invention, the "transformant" means the entirety or a part of the living matter such as cell produced by transformation. Examples of the transformant include prokaryotic cell, yeast, animal cell, plant cell, insect cell  
5 and the like. Depending on the target, the transformant is also sometimes called transformed cell, transformed tissue, transformed host and the like. The cell used in the present invention may also be a transformant.

[0009]

10 Examples of the prokaryotic cell used for genetically-engineered technique relating to the present invention include prokaryotic cells belonging to the genus *Escherichia*, the genus *Serratia*, the genus *Bacillus*, the genus *Brevibacterium*, the genus *Corynebacterium*, the genus *Microbacterium*, the genus  
15 *Pseudomonas* and the like, specifically, *Escherichia* XL1-Blue, *Escherichia* XL2-Blue, *Escherichia* DH1 and the like. These cells are specifically described in, for example, "Molecular Cloning (3rd edition)" by Sambrook, J and Russell, D.W., Appendix 3 (Volume 3), Vectors and Bacterial strains. A3.2  
20 (Cold Spring Harbor USA 2001).

[0010]

The "vector" relating to the present invention means a vector capable of transferring a desired polynucleotide sequence into an object cell. Examples of such vector include  
25 those capable of autonomous replication in a host cell such as prokaryotic cell, yeast, animal cell, plant cell, insect cell, animal individual and plant individual and the like, or permitting incorporation into a chromosome, and containing a promoter at a position suitable for polynucleotide  
30 transcription and the like.

Of such vectors, a vector suitable for cloning is sometimes indicated as a "cloning vector". Such cloning vector generally has multiple cloning sites containing plural restriction enzyme sites. At present, there are many vectors  
35 usable for gene cloning in the pertinent field, and they are

sold by distributors with different names since they are slightly different (e.g., kind and sequence of restriction enzymes at multi cloning sites). For example, representative ones are described (distributors are also described) in  
5 "Molecular Cloning (3rd edition)" by Sambrook, J and Russell, D.W., Appendix 3 (Volume 3), Vectors and Bacterial strains. A3.2 (Cold Spring Harbor USA, 2001), and those of ordinary skill in the art can use them as appropriate according to the object.

10 [0011]

The "vector" relating to the present invention also includes "expression vector", "reporter vector", and "recombinant vector". The "expression vector" means a nucleic acid sequence wherein various regulatory elements in addition  
15 to a structural gene and a promoter that regulates the expression thereof are operably linked in the host cell. Examples of the "regulatory element" include terminator, selection marker such as a drug resistance gene, and one containing an enhancer, and the like. It is well known to  
20 those of ordinary skill in the art that the type of an expression vector of living matter (e.g., animal) and the kind of the regulatory element to be used may vary depending on the host cell.

[0012]

25 Examples of the "recombinant vector" relating to the present invention include (a) lambda FIX vector (phage vector) for screening for genome library, (b) lambda ZAP vector (phage vector) for screening for cDNA, (c) pBluescript II SK+/- vector, pGEM vector, pCR2.1 vector (plasmid vector) for cloning of  
30 genomic DNA, and the like. Examples of the "expression vector" include pSV2/neo vector, pcDNA vector, pUC18 vector, pUC19 vector, pRc/RSV vector, pLenti6/V5-Dest vector, pAd/CMV/V5-DEST vector, pDON-AI-2/neo vector, pMEI-5/neo vector and the like (plasmid vector) and the like. Examples of the "reporter  
35 vector" include pGL2 vector, pGL3 vector, pGL4.10 vector,

pGL4.11 vector, pGL4.12 vector, pGL4.70 vector, pGL4.71 vector, pGL4.72 vector, pSLG vector, pSLO vector, pSLR vector, pEGFP vector, pAcGFP vector, pDsRed vector and the like. These vectors can be utilized as appropriate by reference to the  
5 aforementioned Molecular Cloning reference.

[0013]

In relation to the present invention, examples of the technique for introducing a nucleic acid molecule into a cell include transformation, transduction, transfection and the like.  
10 As such introduction techniques, for example, the methods described in Ausubel F. A. et al. ed. (1988), Current Protocols in Molecular Biology, Wiley, New York, NY; Sambrook J. et al. (1987), Molecular Cloning: A Laboratory Manual, 2nd Ed. and 3rd Ed.; Cold Spring Harbor Laboratory Press, Cold Spring Harbor,  
15 NY; extra issue, Experimental Medicine "transgene & expression analysis experiment method" YODOSHA CO., LTD., 1997 and the like, and the like can be specifically mentioned. Examples of the technique for confirming intracellular introduction of a gene include Northern blot analysis, Western blot analysis or  
20 other well-known conventional techniques and the like.

[0014]

In relation to the present invention, examples of the introduction method of vector include transfection, transduction, transformation and the like (e.g., calcium  
25 phosphate method, liposome method, DEAE-dextran method, electroporation method, method using particle gun (gene gun) etc.).

[0015]

The cryopreservation method of the present invention is a  
30 cryopreservation method characterized by comprising the following (1) to (3):

- (1) a first step of bringing a tissue derived from a pluripotent stem cell into contact with a cell protection solution that contains sulfoxide and chain polyol,
- 35 (2) a second step of maintaining, in a cryopreservation

solution, the pluripotent stem cell-derived tissue that was brought into contact with the cell protection solution in the first step, and

(3) a third step of cryopreserving, in the presence of a  
5 coolant, the pluripotent stem cell-derived tissue that was maintained in the cryopreservation solution in the second step, .  
[0016]

In the present invention, the "stem cell" refers to a cell that maintains the same differentiation capacity even  
10 after cell division, and the cell can regenerate a tissue when the tissue is injured. Here, the stem cell may be an embryonic stem cell (ES cell) or a tissue stem cell (also called tissular stem cell, tissue-specific stem cell or somatic stem cell), or an artificial pluripotent stem cell (iPS cell: induced  
15 pluripotent stem cell) but is not limited thereto. As is appreciated from the fact that the above-mentioned stem cell-derived tissue cell can regenerate a tissue, it is known that the stem cell can differentiate into a normal cell close to one in a living body.

20 [0017]

Stem cells are available from given organizations, or a commercially available product can also be purchased. For example, human embryonic stem cells, KhES-1, KhES-2 and KhES-3, are available from Kyoto University's Institute for Frontier  
25 Medical Sciences. Examples of the mouse embryonic stem cell include EB5 cell and the like.

[0018]

Stem cells can be maintained by culturing according to a method known per se. For example, stem cells can be maintained  
30 by feeder cell-free culture supplemented with fetal calf serum (FCS), Knockout Serum Replacement (KSR), and LIF.

[0019]

In the present invention, the "pluripotent stem cell" refers to a stem cell that can be cultured in vitro and has an  
35 ability to differentiate into any cell (triploblast (ectoderm,

mesoderm, endoderm)-derived tissue) constituting a living body except for placenta (pluripotency), including an embryonic stem cell (ES cell). The "pluripotent stem cell" is obtained from fertilized egg, clone embryo, reproductive stem cell, and stem  
5 cell in a tissue. It also includes a cell having artificial pluripotency similar to that of embryonic stem cells, after introducing several kinds of genes into a somatic cell (also called artificial pluripotent stem cell). Pluripotent stem cell can be produced by a method known per se. Examples of the  
10 production method include the methods described in Cell 131(5) pp. 861-872 (2007), Cell 126(4) pp. 663-676 (2006) and the like.  
[0020]

In the present invention, the "embryonic stem cell (ES cell)" refers to a stem cell having a self replication ability  
15 and multipotency (i.e., "pluripotency"), which is a pluripotent stem cell derived from an early embryo. Embryonic stem cell was first established in 1981, and has also been applied to the generation of knockout mouse since 1989. In 1998, a human embryonic stem cell was established, which is also being  
20 utilized for regenerative medicine.  
[0021]

In the present invention, the "artificial pluripotent stem cell" refers to a cell induced to have multipotency by directly reprogramming a differentiated cell such as fibroblast  
25 etc. by the expression of several kinds of genes such as Oct3/4, Sox2, Klf4, Myc and the like, which was established by Yamanaka et al. in mouse cell in 2006 (Takahashi K, Yamanaka S. Cell. 2006, 126(4), p 663-676). In 2007, it was also established in human fibroblast, and has multipotency similar to that of  
30 embryonic stem cells (Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. Cell. 2007, 131(5), p 861-872.; Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R, Slukvin II, Thomson JA., Science. 2007, 318(5858), p 1917-  
35 1920.; Nakagawa M, Koyanagi M, Tanabe K, Takahashi K, Ichisaka

T, Aoi T, Okita K, Mochiduki Y, Takizawa N, Yamanaka S. Nat Biotechnol., 2008, 26(1), p 101-106).

[0022]

In the present invention, the "differentiation" refers to  
5 a phenomenon wherein two or more types of cells having  
morphologically and/or functionally different qualities are  
generated in a daughter cell population derived from the  
division of a single cell. Therefore, the process in which a  
cell population (cell lineage) derived from a cell having no  
10 detectable special characteristics by nature comes to show  
clear characteristics such as production of a particular  
protein and the like is also encompassed in the differentiation.  
It is generally considered at present that cell differentiation  
is a state of a particular gene group in the genome being  
15 expressed, and the cell differentiation can be identified by  
searching for an intracellular or extracellular factor or  
condition that causes such gene expression state. In principle,  
the result of cell differentiation is stable, and  
differentiation into other type of cell occurs only  
20 exceptionally particularly in animal cells.

[0023]

In the present invention, the "tissue" refers to a  
structure of a cell population, which has a conformation  
wherein plural kinds of cells different in the shape and  
25 property are sterically configured in a given pattern, and the  
"tissue derived from a pluripotent stem cell" in the present  
invention refers to an aggregate of cells obtained by induction  
of differentiation of a pluripotent stem cell, which is a  
structure of a cell population, which has a conformation  
30 wherein plural types of cells different in the shape and  
property are sterically configured in a given pattern.

[0024]

Examples of the cell obtained by induction of  
differentiation of a pluripotent stem cell include cerebral  
35 nerve cell, diencephalic nerve cell, hypothalamus nerve cell,

basal nucleus nerve cell, cerebellum nerve cell, intestinal  
tissue cell, cardiac myocyte, pancreatic cell, hepatic cell,  
and progenitor cells thereof. Specifically, it can be produced  
based on WO 2009/148170, J Neurosci. 2011 Feb 2; 31(5): 1919-33,  
5 Nat Neurosci. 2010 Oct; 13(10): 1171-80, Cell Stem Cell. 2008  
Nov 6; 3(5): 519-32, Proc Natl Acad Sci USA. 2008 Aug 19;  
105(33): 11796-801, Nature. 2011 Feb 3; 470(7332): 105-9, Nat  
Biotechnol. 2011 Mar; 29(3): 267-72, Cell Stem Cell. 2011 Feb  
4; 8(2): 228-40, Development. 2011 Mar; 138(5): 861-71, Nat  
10 Biotechnol. 2006 Nov; 24(11): 1402-11.

[0025]

In the present invention, the "cranial nerve tissue"  
means a structure wherein, in the cerebrum, diencephalic,  
midbrain, cerebellum and epencephalon of a living body, at  
15 least plural kinds of the cells constituting each nerve layer  
and progenitor cells thereof (for example, in the case of  
cerebrum, Tbr1 positive cells specific to the 6th layer, Crip2-  
positive cells specific to the 5th layer, Brn2-positive cells  
specific to the 2nd-3rd layers and the like) are sterically  
20 arranged in layers. As a part of the cranial nerve tissue, a  
retinal tissue can be mentioned. The "retinal tissue" means a  
retinal tissue wherein at least plural kinds of cells such as  
visual cells, horizontal cells, bipolar cells, amacrin cells,  
retinal ganglion cells, progenitor cells thereof and the like,  
25 which constitute respective retinal layers in living retina,  
are sterically arranged in layers. With regard to each cell,  
which cell constitutes which retinal layer can be confirmed by  
a known method, based on the expression of, for example, cell  
marker (Chx10 (bipolar cell), L7 (bipolar cell), Tuj1 (ganglion  
30 cell), Brn3 (ganglion cell), Calretinin (amacrin cell),  
Calbindin (horizontal cell), Recoverin (visual cell), Rhodopsin  
(visual cell), RPE65 (pigment epithelial cell), Mitf (pigment  
epithelial cell) and the like).

For example, the retinal tissue can be produced by  
35 differentiation of human ES cells, specifically, by the methods



described in Nature 472, p51-56 (2011) and WO2011/055855.

[0026]

In the present invention, the "cryoprotection solution" refers to a mixture of a cryoprotectant and a solvent. The  
5 "cryoprotectant" is a substance added to prevent various disorders caused by freezing, in an attempt to maintain the function and survival rate of the cell as much as possible during the cryopreservation of the cells. The cryoprotection solution can be said and means the same as a cell protection  
10 solution since it protects cells during freezing.

[0027]

In the present invention, the cell protection solution (cryoprotection solution) contains sulfoxide and chain polyol as cryoprotectants, and preferably contains sulfoxide, chain  
15 polyol and oligosaccharide. To be specific, for example, sulfoxides such as dimethyl sulfoxide (DMSO) and the like; chain polyols such as ethylene glycol, glycerol, propanediol, propylene glycol, butanediol, polyethylene glycol and the like, and preferably further contains oligosaccharides such as  
20 sucrose, trehalose, lactose, raffinose and the like. When desired, an amide compound such as acetamide and the like, percoll, ficoll 70, ficoll 70000, polyvinylpyrrolidone and the like may be added.

[0028]

25 Examples of the solvent include buffers such as saline, PBS, EBSS, HBSS and the like, culture media for culturing cells, tissues and the like such as DMEM, GMEM, RPMI and the like, serum, serum substitute (Knock Out Serum Replacement: Invitrogen), mixtures thereof and the like.

30 [0029]

In the present invention, the final concentration of sulfoxide in a cell protection solution (cryoprotection solution) is, for example, 5 to 15%(w/v), preferably 9 to 13%(w/v), more preferably about 11%(w/v).

35 [0030]

In the present invention, the final concentration of chain polyol in a cell protection solution (cryoprotection solution) is, for example, 4 to 15%(w/v), preferably 4.5% to 8%(v/v), more preferably about 5.5%(v/v).

5 [0031]

In the present invention, the final concentration of oligosaccharide in a cell protection solution (cryoprotection solution) is, for example, 5 to 20%(w/v), preferably 8 to 12%(w/v), more preferably about 10%(w/v).

10 [0032]

In the present invention, the "cryopreservation solution" refers to a medium for cryopreservation of a tissue derived from a pluripotent stem cell. As a cryopreservation solution, commercially available products such as cell BANKER 1, 1plus, 2,  
15 3 (JUJI FIELD INC.), TC-Protector (DS Pharma Biomedical Co., Ltd.), Freezing Medium for human ES/iPS Cells (Reprocell Incorporated), CryoScarless DMSO free (BioVerde), StemCell Keep (BioVerde), EFS solution (NK system) and the like can also be used.

20 The cryopreservation solution may be a mixture of a cryoprotectant and a solvent. As the cryoprotectant and the solvent, those described above can be mentioned.

[0033]

The cryopreservation solution in the present invention  
25 preferably contains dimethyl sulfoxide, acetamide and propylene glycol.

[0034]

In the present invention, the concentration of dimethyl sulfoxide in the cryopreservation solution is preferably 1 to  
30 4M, the concentration of acetamide is preferably 0.5 to 2M, and the concentration of propylene glycol is preferably 1.5 to 6M.

[0035]

The first step of the cryopreservation method of the present invention is a step of bringing a tissue derived from a  
35 pluripotent stem cell into contact with a cell protection

solution that contains sulfoxide and chain polyol before freezing.

[0036]

In the above-mentioned first step, a tissue derived from  
5 a pluripotent stem cell is brought into contact with a cell protection solution containing sulfoxide and chain polyol.

To "bring a tissue derived from a pluripotent stem cell into contact with a cell protection solution that contains sulfoxide and chain polyol", a tissue derived from a  
10 pluripotent stem cell may be transferred into a cell protection solution containing sulfoxide and chain polyol, or a cell protection solution containing sulfoxide and chain polyol may be added to a tissue derived from a pluripotent stem cell.

The time for bringing a tissue derived from a pluripotent  
15 stem cell into contact with a cell protection solution containing sulfoxide and chain polyol is, for example, 1 min to 180 min, preferably 5 min to 60 min, more preferably 15 min to 30 min. The temperature at which a tissue derived from a pluripotent stem cell is brought into contact with a cell  
20 protection solution containing sulfoxide and chain polyol is, for example, -10°C to 40°C, preferably 0°C to 25°C, more preferably 0°C to 8°C.

[0037]

The density of the tissue derived from a pluripotent stem  
25 cell in the contact system in the above-mentioned first step (for example, density of the tissue derived from a pluripotent stem cell in the cell protection solution) is, for example, based on the number of aggregates, about 1 to 1000 aggregates/mL, preferably 1 to 100 aggregates/mL. The number  
30 of cells per one aggregate is about  $10^3$  to  $10^6$  cells.

[0038]

A cell culture vessel used for contacting a cell protection solution is not particularly limited, and can be appropriately determine by those of ordinary skill in the art.  
35 Examples of such vessel include flask, tissue culture flask,

dish, petri dish, tissue culture dish, multidish, microplate, microwell plate, micropore, multiplate, multiwell plate, chamber slide, schale, tube, tray, culture bag, and roller bottle.

5 [0039]

The second step of the cryopreservation method of the present invention is a step of maintaining the tissue derived from a pluripotent stem cell, which was brought into contact with the cell protection solution, in a cryopreservation  
10 solution.

[0040]

In the above-mentioned second step, the tissue derived from a pluripotent stem cell, which was brought into contact with the cell protection solution in the first step, is  
15 maintained in a cryopreservation solution.

The density of the tissue derived from a pluripotent stem cell in the cell preservation solution in the above-mentioned second step is, for example based on the number of aggregates, about 1 to 1000 aggregates/mL, preferably 1 to 100  
20 aggregates/mL. The number of cells per one aggregate is about  $10^3$  to  $10^6$  cells.

[0041]

The third step of the cryopreservation method of the present invention is a step of cryopreserving the tissue  
25 derived from a pluripotent stem cell, which was maintained in the cryopreservation solution, in the presence of a coolant.

[0042]

As a method for "cryopreserving" tissues and the like, several methods are known. A representative cryopreservation  
30 method is, for example, a method involving freezing at a slow rate of 0.1 to 10°C/min for a long time. This method can be performed using apparatuses, tools and the like such as program freezer, BICELL (NIHON FREEZER CO., LTD.) and the like.

[0043]

35 As a rapid cryopreservation method, a method involving

application of a phenomenon of vitrification that occurs when a crystalline liquid or gas is rapidly solidified at not more than the glass transition temperature without crystallization can be mentioned. This method is superior in that tissue,  
5 embryo and ovum immersed in advance in a preservation solution with a high concentration can be stably cryopreserved by a simple operation of vitrification in a short time.

[0044]

Here, the rapid cryopreservation method is a freezing  
10 method of a biological sample, which includes casting the sample into a coolant such as liquid nitrogen and the like. For example, a method involving placing a tissue derived from a pluripotent stem cell and a cryopreservation solution in a cryotube on ice, and immersing the aforementioned cryotube in a  
15 coolant with tweezers can be mentioned. The time from maintaining a tissue derived from a pluripotent stem cell in a cryopreservation solution to casting same into a coolant is preferably as short as possible, which is within 30 seconds, preferably within 10 seconds.

20 [0045]

The "coolant" to be used in the present invention is preferably one capable of causing vitrification of cells, and a coolant generally at -20°C or below, preferably -80°C or below, more preferably -150°C or below, can be used.

25 [0046]

Specific examples of the coolant include liquid nitrogen, slush nitrogen, liquid helium, liquid propane, and ethane slush, with preference given to liquid nitrogen and slush nitrogen. Slush nitrogen is nitrogen obtained by retaining liquid  
30 nitrogen under reduced pressure to lower the liquid nitrogen temperature to -205 to -210°C, which is lower than -196°C at normal pressure (Huang et al., Human Reproduction, Vol. 20, No. 1, pp. 122-128 (2005)). When slush nitrogen is used as a coolant, preservation by vitrification can be performed by an  
35 apparatus such as Vit-Master™ (IMT, Nes Ziona, Israel) and the

like.

[0047]

The temperature lowering rate for cryopreservation in the presence of a coolant is, for example, not less than 10°C/min, preferably not less than 30°C/min, more preferably not less than 50°C/min, particularly preferably not less than 100°C/min.

[0048]

The time necessary for cryopreservation in the presence of a coolant to reach a desired cryopreservation temperature (e.g., -196°C for liquid nitrogen) from ambient temperature is, for example, within 5 min, more preferably within 3 min, further preferably within 1 min.

Examples

[0049]

The Examples of the present invention are explained in more detail in the following.

[0050]

(Establishment of RAX knock-in human ES cells)

Human ES cell line having GFP knocked in the RAX gene locus, which is one of the marker genes of retinal progenitor cells, was prepared.

Zinc Finger Nuclease (ZFN) that specifically cleaves RAX gene on genome DNA of human ES cell line (KhES-1: human ES cell line established by Kyoto University) was purchased from Sigma Aldrich. Using the human ES cells dispersed into single cells, a ZFN encoding mRNA and knock-in vector containing GFP and a drug selective marker, neomycin resistance gene, were co-transfected therein by an electroporation method, and the cells were plated on the neomycin resistance mouse fibroblast which was treated with mitomycin C. The G418 was added to the culture medium on the following day of plating, and drug selection was performed. The colony of the obtained resistance clones was picked up and subsequently cultured, and then knock-in cells were selected by PCR method and Southern blot method resulting in establishment of the RAX::GFP knock-in human ES

cell line.

[0051]

(Induction of differentiation of RAX knock-in human ES cells into retinal tissue)

5 Using the established RAX::GFP knock-in human ES cells, differentiation into retinal tissue was induced.

RAX::GFP knock-in human ES cells (derived from KhES-1) were cultured according to the method described in "Ueno, M. et al. PNAS 2006, 103(25), 9554-9559" "Watanabe, K. et al. Nat  
10 Biotech 2007, 25, 681-686" and used for the experiment.

As the medium, DMEM/F12 medium (Invitrogen) added with 20% KSR (Knockout Serum Replacement; Invitrogen), 0.1 mM 2-mercaptoethanol, 5 to 10 ng/ml bFGF and the like was used. For induction of differentiation into retinal tissue by floating  
15 culture, ES cells were dispersed into single cells in 0.25% trypsin-EDTA (Invitrogen), and floated in 150  $\mu$ l differentiation medium at  $9 \times 10^3$  cells per well of a non-cell adhesive 96 well culture plate (SUMILON spheroid plate, SUMITOMO BAKELITE) to allow for rapid formation of aggregates,  
20 which were cultured at 37°C, 5% CO<sub>2</sub>.

As the differentiation medium therefor, a serum-free medium (G-MEM medium added with 20% KSR, Y27632 and the like) was used. From day 2 of culture, Matrigel was added to the culture. After the start of the differentiation induction,  
25 expression of GFP in the aggregates was observed by fluorescence microscopic observation from around day 12 and, on around day 14, a neuroepithelium-like structure expressing GFP was formed on the periphery of the aggregates (Fig. 1, Fig. 2). During the period of from day 18 to day 30, the  
30 neuroepithelium-like structure was separated from the aggregates with tweezers, and subsequently cultured in a non-adhesive plastic schale after addition of fetal calf serum and retinoic acid (Fig. 3, Fig. 4). A section was prepared, and the state of differentiation was analyzed by a fluorescence  
35 immunostaining method (Fig. 5). For example, it was shown that

a neuroepithelial structure after 40 days from the start of the differentiation induction is composed of GFP positive cells expressing RAX gene, and that, in the GFP positive cells, Pax6 which is one of the retinal progenitor cell marker genes positive cell, Chx10 which is one of the bipolar cell marker genes positive cell, and Brn3 which is one of the ganglion cell marker genes positive cell are arranged in layers to form a retinal tissue (Fig. 5).

[0052]

10 Comparative Example 1 (Cryopreservation of retinal tissue obtained by induction of differentiation of a human ES cell)

The retinal tissues obtained by differentiation induction were cryopreserved at a temperature lowering rate of not less than 100°C/min.

15 DMEM/F12 medium added with 2M dimethyl sulfoxide (DMSO), 1M acetamide and 3M propylene glycol (DAP213) was used as a cryopreservation solution. About 10 retinal tissues were collected in a 15 ml polypropylene tube from the culture plate followed by removal of the supernatant and addition of 200  
20 µl of the cryopreservation solution, and the retinal tissue was transferred to a cryotube together with the cryopreservation solution. The cryotube was immediately immersed in liquid nitrogen with tweezers, and cryopreserved at a temperature lowering rate of not less than 100°C/min. The frozen tube was  
25 preserved in a freezer at -150°C until thawing.

The cryotube was taken out from the freezer at -150°C, and a medium warmed to 37°C in advance in a 37°C water bath was added to the cryotube to thaw the tissue. The mixture was dispensed to a 15 ml tube, and the retinal tissue was placed in  
30 a medium (10 ml) warmed to 37°C followed by removal of the supernatant. The tissue was washed with PBS (10 ml) and added to a floating culture dish containing a medium (DMEM/F12 medium added with N2, 10% FBS, retinoic acid and the like) (retinal tissue culture medium), and cultured at 37°C. A microscopic  
35 observation and fluorescence microscopic observation were



performed from the following day of thawing, and the cell survival state and the appearance of the epithelial structure were compared with those of the retinal tissue (Fig. 6 A, B) free of cryopreservation, and success or failure of the  
5 cryopreservation was checked.

As a result, almost all cells were dead, and a lot of debris of the dead cells was observed. The expression of GFP was scarcely observed. Therefore, it was shown that mere cryopreservation at a temperature lowering rate of not less  
10 than 100°C/min does not result in the cryopreservation of the retinal tissue (Fig. 6 C, D).

[0053]

Comparative Example 2 (Cryopreservation of retinal tissue obtained by induction of differentiation of a human ES cell by  
15 freezing after penetration treatment in cryoprotectant (11.0% (w/v) dimethyl sulfoxide (DMSO))

Before freezing, a retinal tissue obtained by induction of differentiation was subjected to a penetration treatment in a solution containing dimethyl sulfoxide (DMSO) as a  
20 cryoprotectant, and cryopreserved at a temperature lowering rate of not less than 100°C/min.

About 10 to 20 retinal tissues were collected in a 15 ml polypropylene tube from the culture plate followed by removal of the supernatant and addition of a solution (1 ml)  
25 containing a cryoprotectant cooled in advance on ice, and the mixture was stood on ice for 15 min to 30 min. As the solution containing a cryoprotectant, the aforementioned retinal tissue culture medium added with 11.0% (w/v) dimethyl sulfoxide (DMSO) was used. The solution containing a cryoprotectant was removed,  
30 DAP213 (200  $\mu$ l) was added as a cryopreservation solution, and the retinal tissue was transferred to a cryotube together with the cryopreservation solution. The cryotube was immediately immersed in liquid nitrogen with tweezers, and cryopreserved at a temperature lowering rate of not less than 100°C/min. The  
35 frozen tube was preserved in a freezer at -150°C until thawing.

When cryopreserved at a temperature lowering rate of not less than 100°C/min after a penetration treatment using a retinal tissue culture medium containing 11.0% (w/v) dimethyl sulfoxide (DMSO) as a cryoprotectant, the retinal tissue  
5 expressing RAX drastically reduced as compared to the control without freezing (Fig. 6 E, F).

[0054]

Example 1 (Cryopreservation of retinal tissue obtained by induction of differentiation of a human ES cell, by freezing  
10 after penetration treatment with cryoprotectants (11.0% (w/v) dimethyl sulfoxide (DMSO) and 5.55% (w/v) ethylene glycol))

Performed in the same manner as in Comparative Example 2 except that a retinal tissue obtained by differentiation induction was subjected to a penetration treatment using a  
15 solution containing 11.0% (w/v) dimethyl sulfoxide (DMSO) and 5.55% (w/v) ethylene glycol (EG) as cryoprotectants.

When cryopreserved at a temperature lowering rate of not less than 100°C/min after a cryoprotectant penetration treatment using a retinal tissue culture medium containing  
20 11.0% (w/v) dimethyl sulfoxide (DMSO) and 5.55% (w/v) ethylene glycol (EG), the preserving property of a retinal tissue expressing RAX was improved (Fig. 6 G, H) and the layer structure was found to have been maintained (Fig. 8 A, B), relative to the aforementioned cryoprotectant penetration  
25 treatment using a retinal tissue culture medium containing 11.0% (w/v) dimethyl sulfoxide (DMSO).

[0055]

Example 2 (Cryopreservation of retinal tissue obtained by induction of differentiation of a human ES cell, by freezing  
30 after penetration treatment with cryoprotectants (11.0% (w/v) dimethyl sulfoxide (DMSO), 5.55% (w/v) ethylene glycol (EG) and 10% (w/v) sucrose))

Performed in the same manner as in Comparative Example 2 except that a retinal tissue obtained by differentiation  
35 induction was subjected to a penetration treatment using a

solution containing 11.0% (w/v) dimethyl sulfoxide (DMSO), 5.55% (w/v) ethylene glycol (EG) and 10% (w/v) sucrose as cryoprotectants.

When cryopreserved at a temperature lowering rate of not less than 100°C/min after a cryoprotectant penetration treatment using a retinal tissue culture medium containing 11.0% (w/v) dimethyl sulfoxide (DMSO), 5.55% (w/v) ethylene glycol (EG) and 10% (w/v) sucrose, the condition comparable to a retinal tissue without cryopreservation was maintained while the intensity of GFP expression was somewhat weak as compared to the retinal tissue without cryopreservation. The preservation property was very good (Fig. 6 I, J), and the layer structure was also maintained (Fig. 8 C, D, E).  
[0056]

Comparative Example 3 (Cryopreservation of retinal tissue obtained by induction of differentiation of a human ES cell, by freezing after penetration treatment with cryoprotectant (sucrose))

Using the aforementioned retinal tissue culture media respectively added with 5% sucrose, added with 10% sucrose, added with 20% sucrose, added with 5.55% EG and 10% sucrose, and added with 11% (w/v) dimethyl sulfoxide (DMSO) and 10% (w/v) sucrose as cryoprotectant penetration solutions, freezing and thawing were performed by processes similar to those mentioned above.

When cryopreserved at a temperature lowering rate of not less than 100°C/min after a penetration treatment using a retinal tissue culture medium added with sucrose alone as a cryoprotectant penetration solution, the cell survival property after thawing was considerably poor at any concentration of 5% (w/v), 10% (w/v) and 20% (w/v) and GFP expression was scarcely observed (Fig. 7 C, D, E, F, G, H), as compared to a control free of freezing (Fig. 7 A, B). Also, when cryopreserved at a temperature lowering rate of not less than 100°C/min after a penetration treatment using a retinal tissue culture medium

containing 5.55% (w/v) EG and 10% (w/v) sucrose, the cell survival property after thawing was considerably poor and GFP expression was scarcely observed (Fig. 7 K, L), as compared to a control free of freezing. When cryopreserved at a  
5 temperature lowering rate of not less than 100°C/min after a penetration treatment using a retinal tissue culture medium containing 11.0% (w/v) dimethyl sulfoxide (DMSO) and 10% (w/v) sucrose, the cell survival property after thawing was poor and GFP expression was weak, as compared to a control free of  
10 freezing, and preservation in a state comparable to a control without freezing was not possible (Fig. 7 I, J).

#### Industrial Applicability

[0057]

According to the present invention, a preservation method  
15 of a tissue derived from a pluripotent stem cell can be provided.

[0058]

This application is based on a patent application No. 2011-258208 filed in Japan (filing date: November 25, 2011),  
20 the contents of which are incorporated in full herein.

In the claims which follow and in the preceding description of the invention, except where the context requires otherwise due to express language or necessary implication, the word "comprise" or variations such as "comprises" or "comprising" is used in an inclusive sense, i.e. to specify the presence of the stated features but not to preclude the presence or addition of further features in various embodiments of the invention.

It is to be understood that, if any prior art publication is referred to herein, such reference does not constitute an admission that the publication forms a part of the common general knowledge in the art, in Australia or any other country.

## Claims

1. A method for cryopreserving a tissue derived from a pluripotent stem cell, comprising the following (1) to (3):  
(1) a first step of bringing a tissue derived from a pluripotent stem cell into contact at 0°C to 8°C with a first solution that is a cell protection solution and contains sulfoxide and chain polyol,  
(2) a second step of maintaining, in a second solution that is a cryopreservation solution, the pluripotent stem cell-derived tissue that was brought into contact with the cell protection solution in the first step, and  
(3) a third step of cryopreserving, in the presence of a coolant, the pluripotent stem cell-derived tissue that was maintained in the cryopreservation solution in the second step;

wherein the sulfoxide is dimethyl sulfoxide and the chain polyol is ethylene glycol.

2. The cryopreservation method according to claim 1, wherein the cell protection solution that contains sulfoxide and chain polyol is a cell protection solution that contains sulfoxide, chain polyol and oligosaccharide.

3. The cryopreservation method according to claim 2, wherein the cell protection solution has a sulfoxide concentration of 5 to 15%, a chain polyol concentration of 4 to 15%, and an oligosaccharide concentration of 5 to 20%.

4. The cryopreservation method according to claim 2 or 3, wherein the oligosaccharide is sucrose.

5. The cryopreservation method according to any one of claims 1 to 4, wherein said pluripotent stem cell is a human

pluripotent stem cell.

6. The cryopreservation method according to any one of claims 1 to 5, wherein the tissue is a cranial nerve tissue.

7. The cryopreservation method according to any one of claims 1 to 5, wherein the tissue is a retinal tissue.

8. The cryopreservation method according to any one of claims 1 to 7, wherein the third step is performed at a temperature lowering rate of not less than 10°C/min.

9. The cryopreservation method according to any one of claims 1 to 7, wherein the third step is performed at a temperature lowering rate of 0.1 to 10°C/min.

10. The cryopreservation method according to any one of claims 1 to 9, wherein the coolant is liquid nitrogen.

11. The cryopreservation method according to any one of claims 1 to 10, wherein the cryopreservation solution is a cryopreservation solution that contains dimethyl sulfoxide, acetamide and propylene glycol.

12. The cryopreservation method according to claim 11, wherein the concentration of dimethyl sulfoxide is 1 to 4M and the concentration of acetamide is 0.5 to 2M and the concentration of propylene glycol is 1.5 to 6M.

1/5

FIG.1




FIG.2




FIG.3






FIG.4






FIG.5


A:GFP



B:Chx10



C:Pax6



D:Brn3




FIG.6







FIG.7



5/5  
FIG.8

DMSO/EG



DMSO/EG/Sucrose

